October 4, 2017 09:37 AM EDT
News Briefing

Con­gress fires an­oth­er sal­vo at Al­ler­gan’s Mo­hawk deal; AI out­fit rais­es $60M for dis­cov­ery ef­fort

Shehla Shakoor

Managing Director

→ Al­ler­gan’s move to try and steer around an IPR re­view of its patents for its $1.5 bil­lion drug Resta­sis by hand­ing them over to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times